Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: health

Dr. Thomas Ehmer, Ph.D. — Merck KGaA Darmstadt, Germany — Quantum Computing Innovation In Pharma

Quantum Computing Innovation In Pharma — Dr. Thomas Ehmer, Ph.D. — Merck KGaA, Darmstadt, Germany

Dr. Thomas Ehmer, Ph.D. (https://www.linkedin.com/in/tehmer/) is a seasoned technology strategist with over two decades of experience in IT innovation, business development, and R&D within the pharmaceutical industry, and co-founder of the Quantum Interest Group, at Merck KGaA Darmstadt, Germany (https://www.emdgroup.com/en).

Dr. Ehmer currently is in the Sector Data Office — AI Governance and Innovation Incubator at Merck KGaA Darmstadt, Germany, where he scouts emerging and disruptive technologies, demonstrating their potential value for R&D applications, with a focus on quantum technologies.

Throughout his career at Merck KGaA Darmstadt, Germany, Dr. Ehmer has played a pivotal role in shaping IT strategy, business process optimization, and digital transformation across the entire pharmaceutical value chain, currently focusing on transparent AI and how and where emerging technology can help patients live a better life. His expertise spans technology scouting, business analysis, and IT program leadership, having successfully driven major global projects.

Beyond his corporate career, Dr. Ehmer is an active private seed investor and has contributed to quantum computing research and applications in drug discovery, authoring publications on the potential of quantum computing and machine learning in pharmaceutical R&D (https://onlinelibrary.wiley.com/doi/10.1002/9783527840748.ch26).

Continue reading “Dr. Thomas Ehmer, Ph.D. — Merck KGaA Darmstadt, Germany — Quantum Computing Innovation In Pharma” | >

Virginia Tech researchers explore creatine therapy for brain health

Creatine is popularly known as a muscle-building supplement, but its influence on human muscle function can be a matter of life or death.

Creatine is very crucial for energy-consuming cells in skeletal muscle throughout the body, but also in the brain and in the heart.

Flavoproteins as probes for in cell ESR spectroscopy

The drugs, sutezolid and delpazolid, have demonstrated strong antimicrobial activity and a notably better safety profile compared to linezolid, with the potential to replace this current cornerstone in the treatment of drug-resistant TB.

The findings were published in two articles in The Lancet Infectious Diseases. Research partners in Europe included Radboud University Medical Center in the Netherlands and the German Center for Infection Research (DZIF), Munich, the Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, the Center for International Health at LMU University Hospital and Helmholtz Munich.

AI Does Something Subtly Bizarre If You Make Typos While Talking to It

New research suggests that medical AI chatbots are woefully unreliable at understanding how people actually communicate their health problems.

As detailed in yet-to-be-peer-reviewed study presented last month by MIT researchers, an AI chatbot is more likely to advise a patient not to seek medical care if their messages contained typos. The errors AI is susceptible to can be as seemingly inconsequential as an extra space between words, or if the patient used slang or colorful language. And strikingly, women are disproportionately affected by this, being wrongly told not to see a doctor at a higher rate than men.

Hybrid model reveals people act less rationally in complex games, more predictably in simple ones

Throughout their everyday lives, humans are typically required to make a wide range of decisions, which can impact their well-being, health, social connections, and finances. Understanding the human decision-making processes is a key objective of many behavioral science studies, as this could in turn help to devise interventions aimed at encouraging people to make better choices.

Researchers at Princeton University, Boston University and other institutes used machine learning to predict the strategic decisions of humans in various games. Their paper, published in Nature Human Behavior, shows that a trained on human decisions could predict the strategic choices of players with high levels of accuracy.

“Our main motivation is to use modern computational tools to uncover the cognitive mechanisms that drive how people behave in strategic situations,” Jian-Qiao Zhu, first author of the paper, told Phys.org.

Treating postoperative delirium as preventable ‘acute brain failure’: Low-cost interventions could have major impact

A new large-scale study spotlights postoperative delirium as a preventable and high-impact complication which is driven by patient frailty and surgical stress—and one that can be addressed through low-cost, evidence-based interventions.

The findings, which appear in JAMA Network Open, provide a call to action for clinicians, health systems, patients, and families to prioritize brain health throughout perioperative care.

“Postoperative delirium isn’t a minor complication—it’s analogous to acute brain failure, a medical emergency that should be recognized and addressed,” said Laurent Glance, MD, a professor of Anesthesiology and Perioperative Medicine at the University of Rochester Medical Center (URMC) and senior author of the study.

Novartis receives approval for first malaria medicine for newborn babies and young infants

Basel, July 8, 2025 – Novartis today announced Coartem® (artemether-lumefantrine) Baby has been approved by Swissmedic as the first malaria medicine for newborns and young infants. The new treatment, also known as Riamet® Baby in some countries, was developed in collaboration with Medicines for Malaria Venture (MMV) to treat the potentially deadly mosquito-borne disease.

Eight African countries also participated in the assessment and are now expected to issue rapid approvals under the Swiss agency’s Marketing Authorization for Global Health Products procedure.1 Novartis plans to introduce the infant-friendly treatment on a largely not-for-profit basis to increase access in areas where malaria is endemic.

“For more than three decades, we have stayed the course in the fight against malaria, working relentlessly to deliver scientific breakthroughs where they are needed most,” said Vas Narasimhan, CEO of Novartis. “Together with our partners, we are proud to have gone further to develop the first clinically proven malaria treatment for newborns and young babies, ensuring even the smallest and most vulnerable can finally receive the care they deserve.”